湿性AMD市場の洞察：規模、傾向、2034年までの予測

According to DelveInsight's latest analysis, the Wet Age-Related Macular Degeneration (Wet AMD) market in the 7 Major Markets (7MM) reached approximately USD 7,783 million in 2023, with projections indicating significant growth by 2034. The report, titled “Wet Age-Related Macular Degeneration (Wet AMD) Market Insights, Epidemiology, and Market Forecast – 2034,” provides a comprehensive examination of Wet AMD, including historical and projected epidemiology, market trends, and key developments across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Gain exclusive access to critical Wet AMD market data! Download DelveInsight’s detailed report for in-depth analysis of market trends, pipeline developments, and innovative therapies @ Wet AMD Market Size https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Highlights from the Wet AMD Market Report

• In June 2025, Amgen initiated a study comparing the effectiveness and safety of ABP 938 against Aflibercept (Eylea®) for treating neovascular age-related macular degeneration. Participants are randomly assigned in a 1:1 ratio to receive either 2 mg (0.05 mL) of ABP 938 or aflibercept via intravitreal injection.
• Also in June 2025, Adverum Biotechnologies Inc. launched a Phase 3 trial targeting a diverse group of patients (both treatment-naïve and experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study assesses a single intravitreal injection of Ixo-vec versus an active comparator, with the primary outcome measuring the average change in best corrected visual acuity (BCVA) at Weeks 52 and 56.
• In the same month, Kodiak Sciences Inc. announced a Phase 3 trial to evaluate the efficacy and safety of intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer in comparison to intravitreal Aflibercept for patients with neovascular (wet) age-related macular degeneration.
• DelveInsight estimates that the total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were around 40 million in 2023.
• The United States reported the highest number of diagnosed prevalent AMD cases in 2023, approximately 14 million, with anticipated increases ahead.
• Among European nations, Germany led with about 6 million diagnosed AMD cases in 2023, while Spain had the lowest at roughly 2 million.
• Japan accounted for nearly 8 million diagnosed AMD cases in 2023, representing about 21% of the 7MM total.
• Age-specific data for the US shows the 70-79 age group most affected by Wet AMD, with around 406,000 cases in 2023.
• In Japan, Dry AMD cases outnumbered Wet AMD, comprising approximately 90% of total AMD cases compared to 10% for Wet AMD in 2023.
• Within Europe, Germany had the highest Wet AMD prevalence at about 595,000 cases, followed by France at roughly 389,000, with Spain at the lowest at approximately 160,000.
• Japan's Wet AMD diagnosed prevalent cases totaled around 840,000 in 2023, making up about 21% of the 7MM.
• In the US, Wet AMD cases were most prevalent in the 70-79 age group (about 407,000), followed by 60-69 (around 393,000), 80+ (approximately 304,000), and 50-59 (roughly 252,000).
• Prominent players in the Wet AMD space include Opthea Limited, Outlook Therapeutics, Kodiak Sciences,Kubota Pharmaceutical Holdings Co., Ltd. , Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.
• Promising therapies in development encompass NT-101 0.05 mM, Eylea® (Aflibercept), Intravitreal aflibercept injection, RGX-314, ABP 938, Aflibercept, Ixo-vec, Ranibizumab, and others.
• In 2023, Kubota completed enrollment in a Phase 2 trial evaluating KVD001 as monotherapy and in combination with aflibercept for Wet AMD. Preliminary data from the trial (presented at ARVO 2023) showed improvements in central subfield thickness and visual acuity, with a favorable safety profile. The trial is ongoing, with results expected in 2024. No regulatory filings yet; the company is exploring further development.

Stay competitive in the Wet AMD landscape. Access DelveInsight’s strategic market analysis and insights now! Click here for details @ Wet AMD Treatment Market Size https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Wet AMD Epidemiology Breakdown in the 7MM

• Total Wet AMD Prevalent Cases
• Wet AMD Diagnosed Prevalent Cases
• Wet AMD Type-Specific Diagnosed Prevalent Cases
• Total Wet AMD Age-Specific Cases

Download the full report to explore the drivers behind Wet AMD epidemiology trends @ Wet AMD Prevalence https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Approved Treatments for Wet Age-Related Macular Degeneration

• BEOVU (Brolucizumab): Developed by Novartis, this anti-VEGF therapy targets Wet AMD by blocking vascular endothelial growth factor, curbing abnormal blood vessel formation and retinal fluid leakage. It supports extended dosing intervals of up to 12 weeks.
• EYLEA (Aflibercept): From Regeneron Pharmaceuticals, EYLEA addresses Wet AMD, diabetic eye conditions, and retinal disorders. As an injectable decoy receptor, it inhibits VEGF-A and PlGF to halt abnormal vessel growth. Typical dosing starts at 2 mg every 4 weeks for the initial 3 months, then every 8 weeks, with ongoing trials exploring less frequent and higher doses.
• VABYSMO (Faricimab): Created by Roche/Genentech, Inc., this is the first bispecific antibody for ocular use, targeting angiopoietin-2 (Ang-2) and VEGF-A. It stabilizes blood vessels by reducing leakage, inflammation, and abnormal growth linked to vision loss.

Innovative Therapies in Development for Wet AMD

• OPT-302: Opthea Limited's 'Trap' inhibitor targets VEGF-C and VEGF-D, addressing blood vessel growth and leakage in Wet AMD and diabetic macular edema. When paired with anti-VEGF-A treatments, it fully inhibits VEGFR-2 and VEGFR-3, overcoming resistance issues.
• KSI-501: Kodiak Sciences Inc.'s novel anti-VEGF biologic offers rapid VEGF inhibition with prolonged effects, potentially reducing the need for frequent injections and enhancing patient adherence and visual outcomes.

Explore the evolving landscape of Wet AMD therapies with DelveInsight's market report. Access expert forecasts and insights—download today! @ Wet AMD Market Drivers and Barriers https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Wet AMD Companies

Opthea Limited, Outlook Therapeutics, Kodiak Sciences,Kubota Pharmaceutical Holdings Co., Ltd. , Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.

Companies in Wet AMD Clinical Trials

A growing number of companies from Japan, South Korea, and Taiwan are contributing to Wet AMD research through sponsored or co-sponsored clinical trials. Below is a comprehensive list of such companies with activity in Phase 1–3 trials for Wet AMD, based on clinical trial registries and company data. This highlights regional innovation in ophthalmology, focusing on novel mechanisms and emerging therapies.

Kubota Pharmaceutical Holdings Co., Ltd.

• Drug Candidate: KVD001 (delpacibart etesevimab)
• Clinical Trial Phase(s): Phase 2
• Mechanism of Action (MOA): Plasma kallikrein inhibitor; reduces retinal edema and vascular leakage by inhibiting kallikrein-mediated pathways in the eye.
• Clinical Trial Registry ID: NCT04656184 (Phase 2, completed enrollment).

Scope of the Wet AMD Market Report

• Coverage: 7MM
• Study Period: 2020- 2034
• Wet AMD Companies: Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, and others.
• Wet AMD Pipeline Therapies: NT-101 0.05 mM, Eylea® (Aflibercept), Intravitreal aflibercept injection, RGX-314, ABP 938, Aflibercept, Ixo-vec, Ranibizumab, and others.
• Wet AMD Therapeutic Assessment: Wet AMD Current Marketed and Wet AMD Emerging Therapies
• Wet AMD Market Dynamics: Wet AMD market drivers and Wet AMD market barriers
• Wet AMD Unmet Needs, KOL’s views, Analyst’s views, Wet AMD Market Access and Reimbursement

Explore the dynamics of the Wet AMD Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Wet AMD Ongoing Clinical Trials Analysis https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

1. Key Insights
2. Wet AMD Market Report Introduction
3. Wet AMD Market Overview at a Glance
4. Wet AMD Market: Future Perspective
5. Executive Summary
6. Key Events
7. Wet AMD Market Disease Background and Overview
8. Wet AMD Epidemiology and Patient Population
9. Patient Journey
10. Wet AMD Marketed Drugs
11. Wet AMD Emerging Drugs
12. Wet AMD: Market Analysis
13. Key Opinion Leaders’ Views
14. Wet AMD SWOT Analysis
15. Wet AMD Unmet Needs
16. Wet AMD Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering high-quality intelligence and analysis to guide strategic decisions. Our expert team, with deep expertise in life sciences and healthcare, provides tailored solutions and real-time insights worldwide. Reach out for accurate, timely data to drive your success.

Related Reports

Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Forecast 2034

DelveInsight’s “Wet Age-related Macular Degeneration (Wet AMD)– Epidemiology Forecast – 2034” report delivers an in-depth understanding of wet AMD, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025” report provides comprehensive insights about 60+ companies and 75+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.The leading Wet AMD Companies developing therapies include - Regeneron Pharmaceuticals, Novartis, Pfizer, Roche, Chengdu Kanghong Biotech, Kodiak Sciences Inc., Opthea Limited, Alkahest Inc., Graybug Vision, REGENXBIO, PanOptica, Inc., Clearside Biomedical, Hemera Biosciences, Ribomic USA Inc., and others.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/